CIRM Clinical Trials

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization.

0

CIRM-Funded Clinical Trials

Photo Credit: UCLA Broad Stem Cell Research Center

Funding Opportunities

Visit our Funding Opportunities page to apply for clinical trial research funding.

See funding opportunities
Find clinical trials
Disease AreasInvestigatorOrganizationPhaseTrial StatusTarget EnrollmentDetail
Age-related macular degeneration Mark Salman Humayun University of Southern California Phase 1 Closed 16
Age-related macular degeneration Jane Stephanie Lebkowski Regenerative Patch Technologies LLC Phase 2 Recruiting N/A
Age-related macular degeneration Dr. Jeffrey H Stern Luxa Biotechnology Phase 1/2 Launching N/A
Alpha Thalassemia Major Dr. Tippi C. MacKenzie University of California, San Francisco Phase 1 Enrolling by invitation 10
Amyotrophic Lateral Sclerosis MD Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 196
Amyotrophic Lateral Sclerosis Professor Clive Niels Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
Amyotrophic Lateral Sclerosis Professor Clive Niels Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Anemia
Bone Marrow Transplant and Viral Infection		 Alice Bertaina Stanford University Phase 1/2 Launching N/A
Anemia Dr. Matthew H Porteus Stanford University Phase 1/2 Launching N/A
Anemia Ryotaro Nakamura City of Hope, Beckman Research Institute Phase 1 Launching N/A
Arthritis
Osteoarthritis		 Dr. Kristen A Johnson Calibr Phase 1 Completed 60
B cell cancers
Leukemia		 Thomas J Kipps University of California, San Diego Phase 1/2 Active, not recruiting 102
B cell cancers
Leukemia		 Dr. David B. Miklos Stanford University Phase 1 Active, not recruiting 56
B cell cancers
Leukemia
Leukemia, Acute Myeloid (AML)		 Dr. Matthew H Porteus Stanford University Phase 1 Recruiting 22
B cell cancers Dr. Paul W Finnegan Angiocrine Bioscience, Inc. Phase 3 Closed 130
Beta Thalassemia Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Completed 5
Bladder or Urinary Tract Disorder James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
Blood Cancer Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
Blood Cancer Thomas J Kipps University of California, San Diego Phase 1 Completed 26
Blood Cancer
Solid Tumors		 Professor Irving L Weissman MD Stanford University Phase 1 Completed 88
Blood Cancer Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1/2 Completed 42
Blood Disorders Ilya Rachman MD PhD Nexcella, Inc. Phase 1 Launching N/A
Bone Marrow Transplant and Viral Infection Michael A. Pulsipher Children’s Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Bone or Cartilage Disease Dr. Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
Bone or Cartilage Disease
Hearing Loss
Intellectual Disability
Metabolic Disorders
Vision Loss		 Dr Robert Hayes Immusoft Corporation Phase 1 Launching N/A
Brain Cancer Dr. Christine E. Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
Brain Cancer Anthony J. Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 234
Brain Cancer
Breast Cancer		 Dr Jana Portnow City of Hope, Beckman Research Institute Phase 1 Recruiting 39
Brain Cancer Dr. Leo D Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Brain Cancer Crystal Mackall Stanford University Phase 1 Recruiting 54
Brain Cancer Dr Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
Brain Cancer Dr. Reena Parada Thomas Stanford University Phase 1 Launching N/A
Brain Cancer Dr. Hideho Okada University of California, San Francisco Phase 1 Launching N/A
Brain Cancer Noriyuki Kasahara University of California, San Francisco Phase 1 Launching N/A
Colon Cancer Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
Colon Cancer Ivan King Tachyon Therapeutics, Inc Phase 1 Launching N/A
Corneal Damage Dr. Sophie X Deng University of California, Los Angeles Phase 1 Recruiting 20
Corneal Damage R. Kim Brazzell Combangio, Inc. Phase 2 Launching N/A
COVID-19
Respiratory Disorders		 Prof. John A. Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
COVID-19 Dr. Michael Matthay MD University of California, San Francisco Phase 2 Completed 120
COVID-19
Respiratory Disorders		 William van der Touw Celularity Inc. Phase 1/2 Closed 86
Cystinosis
Kidney Failure		 Dr. Stephanie Cherqui University of California, San Diego Phase 1/2 Active, not recruiting 6
Danon Disease
Pediatrics		 Dr. Jonathan Schwartz Rocket Pharmaceuticals, Inc. Phase 2 Launching N/A
Developmental Disorders
Spina Bifida		 Dr. Diana L. Farmer University of California, Davis Phase 2 Recruiting 55
Epilepsy Dr. Cory R Nicholas Neurona Therapeutics Phase 1 Recruiting 40
Epilepsy Dr. Cory R Nicholas Neurona Therapeutics Phase 1/2 Launching N/A
Genetic Disorder
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)		 Dr. Donald B. Kohn
Leslie Meltzer		 University of California, Los Angeles
Orchard Therapeutics		 Phase 2 Completed 10
Heart disease associated with Duchenne muscular dystrophy Dr. Linda Marban Capricor, Inc Phase 2 Completed 25
Heart failure Dr. Rachel Ruckdeschel Smith Capricor, Inc Phase 2 Closed 135
Heart failure Dr. Joseph C. Wu Stanford University Phase 1 Recruiting 18
Heart failure Dr. Matthew Pollman Tenaya Therapeutics, Inc. Phase 1 Launching N/A
HIV-related Lymphoma
HIV/AIDS		 Dr Mehrdad Abedi University of California, Davis Phase 1/2 Active, not recruiting 11
HIV/AIDS Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
HIV/AIDS Prof. John A. Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
HIV/AIDS
Immune Disease		 Steven G. Deeks University of California, San Francisco Phase 1/2 Recruiting 18
HIV/AIDS Mr. Daniel Dornbusch Excision BioTherapeutics Phase 1 Active, not recruiting 6
HIV/AIDS Dr. Angelo Manuel Almeida Cardoso Ph.D., MD City of Hope, Beckman Research Institute Phase 1 Launching N/A
Huntington's Disease Dr. Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Immune Disease
Pediatrics
X-linked Chronic Granulomatous Disease		 Dr. Donald B. Kohn University of California, Los Angeles Phase 1/2 Recruiting 16
Immune Disease
Severe Combined Immunodeficiency, X-linked (X-SCID)		 Stephen Gottschalk St. Jude Children’s Research Hospital Phase 1/2 Suspended 28
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, X-linked (X-SCID)		 Dr. Judith A Shizuru
Wendy Pang		 Stanford University
Jasper Therapeutics, Inc.		 Phase 1/2 Recruiting 40
Immune Disease
Leukocyte Adhesion Deficiency		 Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Completed 9
Immune Disease Dr. Jonathan Benjamin ImmPACT-Bio, Inc. Phase 1/2 Launching N/A
Immune Disease Maria Grazia Roncarolo Tr1X Inc. Phase 1 Launching N/A
IPEX Syndrome Dr. Rosa Bacchetta Stanford University Phase 1 Recruiting 30
Kidney Disease Dr. Jeffrey L Veale University of California, Los Angeles Phase 1/2 Launching N/A
Kidney Failure Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 240
Kidney Failure Jeffrey Lawson Humacyte, Inc. Phase 3 Completed 355
Kidney Failure Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
Kidney Failure Daniel Brennan Medeor Acquisition Corp. Phase 3 Completed 30
Kidney Failure Dr. Everett H. Meyer Stanford University Phase 1 Recruiting 22
Leukemia, Acute Myeloid (AML) Dr. Colleen Delaney Nohla Therapeutics Inc. Phase 2 Closed 146
Leukemia, Acute Myeloid (AML) Mark Chao Forty Seven Inc. Phase 1 Closed 258
Leukemia, Acute Myeloid (AML) Joseph Paul Woodard Immune-Onc Therapeutics Phase 1 Recruiting 106
Leukemia, Acute Myeloid (AML) Elizabeth Budde City of Hope, Beckman Research Institute Phase 1 Launching N/A
Leukemia, Acute Myeloid (AML) Rochelle Emery Senti Biosciences, Inc. Phase 1 Launching N/A
Lung Cancer Steven M. Dubinett University of California, Los Angeles Phase 1 Active, not recruiting 24
Lupus, Systemic Lupus Erythematosus (SLE) Dr. Vaneet Sandhu Fate Therapeutics, Inc. Phase 1 Launching N/A
Melanoma Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Melanoma
Skin cancer		 Dr. Antoni Ribas MD/PhD University of California, Los Angeles Phase 1 Closed 5
Melanoma Anusha Kalbasi Stanford University Phase 1 Launching N/A
Multiple Myeloma Rajesh Belani MD Poseida Therapeutics, Inc. Phase 1 Closed 105
Muscle Injury Peter C Belafsky University of California, Davis Phase 1/2 Recruiting 62
Neurological Disorders Amit Etkin Alto Neuroscience Phase 2 Launching N/A
Neurological Disorders
Other		 Prof. Olivia Kim-McManus University of California, San Diego Phase 1/2 Launching N/A
Osteoarthritis Dr. Thomas W Chalberg Jr. Genascence Corporation Phase 1 Launching N/A
Osteonecrosis Nancy E. Lane University of California, Davis Phase 1/2 Completed 58
Parkinson's Disease Krystof S. Bankiewicz Brain Neurotherapy Bio, Inc. Phase 1 Active, not recruiting 11
Parkinson's Disease Dr. Edward Wirth III Aspen Neuroscience Phase 1 Launching N/A
Pediatrics
Sickle Cell Disease		 Dr. Donald B. Kohn University of California, Los Angeles Phase 1 Active, not recruiting 4
Pulmonary Hypertension
Vascular Disease		 Dr. Michael I Lewis Cedars-Sinai Medical Center Phase 1/2 Completed 26
Retinitis Pigmentosa Dr. Henry John Klassen University of California, Irvine Phase 1/2 Completed 28
Retinitis Pigmentosa Henry John Klassen jCyte, Inc. Phase 2 Completed 84
Retinitis Pigmentosa Professor Clive Niels Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
Retinitis Pigmentosa Henry John Klassen jCyte, Inc. Phase 2 Completed 84
Retinitis Pigmentosa Paul Bresge Ray Therapeutics, INC Phase 1 Recruiting N/A
Sarcoma Theodore Scott Nowicki University of California, Los Angeles Phase 1 Closed 5
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) Dr Morton Cowan University of California, San Francisco Phase 2 Recruiting 25
Sickle Cell Disease Dr. De-Fu Zeng City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 3
Sickle Cell Disease Dr Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A
Sickle Cell Disease David Williams Boston Children’s Hospital Phase 2 Recruiting 25
Sickle Cell Disease Mark C. Walters M.D. University of California, San Francisco Phase 1 Not yet recruiting 9
Solid Tumors Dr. Dennis J Slamon University of California, Los Angeles Phase 1 Completed 46
Solid Tumors Dr. Pamela Reilly Contag PhD BioEclipse Therapeutics INC. Phase 1 Recruiting 60
Solid Tumors Pei Wang Eureka Therapeutics, Inc. Phase 1/2 Launching N/A
Solid Tumors Dr. John Le Gall Allogene Therapeutics Phase 1 Launching N/A
Spinal Cord Injury Dr. Jane Stephanie Lebkowski Dr. Geron Corporation Phase 1 Completed 5
Spinal Cord Injury Francois Binette Lineage Cell Therapeutics, Inc. Phase 1/2 Completed 25
Stroke Dr. Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
Stroke Dr. Gary Steinberg Stanford University Phase 1 Recruiting 30
Type 1 diabetes Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
Type 1 diabetes Manasi Jaiman ViaCyte, Inc. Phase 1/2 Completed 49
Type 1 diabetes Dr. William Sietsema Caladrius Biosciences Phase 2 Completed 113
Type 1 diabetes Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8